Personalized diagnostics remains one of the most significant barriers to personalized medicine.

My Diagnostic Development group is building a focused research program to support novel approaches to personalized medicine in breast, prostate, and other cancer types. In collaboration with partners across Ontario and around the world, I am working to create and establish integrated omics approaches to cancer diagnosis.

I work with guideline panels (e.g., ASCO-CAP, TILs in breast cancer) to create better approaches to delivering novel assays in the clinic, bridging the gap between omics discoveries and cancer patients. These approaches are increasingly enabling more personalized treatment for cancer patients across Ontario and beyond.

My work is supported by several global partnerships including the EBCTCG and other clinical trial partners.